ConductScience.org, home

Paper41398167

Heterologous combinations of VSV-GP and native-like trimers elicit autologous Tier 2 HIV antibodies in rabbits.

Radvan F and 15 others. NPJ Vaccines, 2025. Cited by 0 papers, by iCite.

Cite this record

ConductScience Library. Heterologous combinations of VSV-GP and native-like trimers elicit autologous Tier 2 HIV antibodies in rabbits. Papers, record 41398167. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/41398167

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Heterologous combinations of VSV-GP and native-like trimers elicit autologous Tier 2 HIV antibodies in rabbits.
PubMed
Journal
NPJ Vaccines
PubMed
Year
2025
PubMed
Publication types
Journal Article
PubMed
Citations, by iCite
0
iCite
Revised in PubMed
2026-01-22
PubMed

Authors16

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Radvan FFrederik
2Hauser AAlexandra
3Lin LYLi-Yun
4Wilmschen-Tober SSarah
5Schaber MMarion
6Bermejo-Jambrina MMarta
7Agbabiaka TOTariq Oluwakunmi
8Peterhoff DDavid
9Riepler LLydia
10Mendrzyk NNadja
11Beierfuß AAnja
12Speth CCornelia
13Moog CChristianehttps://orcid.org/0000-0002-0916-156X
14von Laer DDorothee
15Wagner RRalf
16Kimpel JJaninehttps://orcid.org/0000-0002-5210-7905

Source PubMed

Download CSV of authors

Topics0

NLM's MeSH indexing of the paper, its major topics first.

None in this release.

Grants2

Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.

Grant, as the record writes itAgencyCountryNIH projectStated by
681032 (EHVA, European HIV Vaccine Alliance)EC | Horizon 2020 Framework Programme (EU Framework Programme for Research and Innovation H2020)PubMed
Project HIVacToGC, Grant 16GW0363KBundesministerium für Bildung und Forschung (Federal Ministry of Education and Research)PubMed

Source PubMed

Download CSV of grants

References50

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
133290394RV144 HIV-1 vaccination impacts post-infection antibody responses.PLoS Pathog2020https://conductscience.org/library/papers/33290394PubMed
218833271Challenges in the development of an HIV-1 vaccine.Nature2008https://conductscience.org/library/papers/18833271PubMed
340260855An HIV Vaccine in the Era of Twice-Yearly Lenacapavir for PrEP - Essential or Irrelevant?N Engl J Med2025https://conductscience.org/library/papers/40260855PubMed
424554655VSV-GP: a potent viral vaccine vector that boosts the immune response upon repeated applications.J Virol2014https://conductscience.org/library/papers/24554655PubMed
531921191Heterologous Combination of VSV-GP and NYVAC Vectors Expressing HIV-1 Trimeric gp145 Env as Vaccination Strategy to Induce Balanced B and T Cell Immune Responses.Front Immunol2019https://conductscience.org/library/papers/31921191PubMed
619843557Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand.N Engl J Med2009https://conductscience.org/library/papers/19843557PubMed
716051804Human immunodeficiency virus type 1 env clones from acute and early subtype B infections for standardized assessments of vaccine-elicited neutralizing antibodies.J Virol2005https://conductscience.org/library/papers/16051804PubMed
825892233Cleavage-independent HIV-1 Env trimers engineered as soluble native spike mimetics for vaccine design.Cell Rep2015https://conductscience.org/library/papers/25892233PubMed
918815292Profiling the specificity of neutralizing antibodies in a large panel of plasmas from patients chronically infected with human immunodeficiency virus type 1 subtypes B and C.J Virol2008https://conductscience.org/library/papers/18815292PubMed
1017699567Early antibodies specific for the neutralizing epitope on the receptor binding subunit of the lymphocytic choriomeningitis virus glycoprotein fail to neutralize the virus.J Virol2007https://conductscience.org/library/papers/17699567PubMed
119466515Cytotoxic T cell and neutralizing antibody responses to human immunodeficiency virus type 1 envelope with a combination vaccine regimen. AIDS Vaccine Evaluation Group.J Infect Dis1998https://conductscience.org/library/papers/9466515PubMed
1232554928Protein-based, but not viral vector alone, HIV vaccine boosting drives an IgG1-biased polyfunctional humoral immune response.JCI Insight2020https://conductscience.org/library/papers/32554928PubMed
1335778473Comparing methods for immobilizing HIV-1 SOSIPs in ELISAs that evaluate antibody binding.Sci Rep2022https://conductscience.org/library/papers/35778473PubMed
1432313928A Randomized Dose-Escalating Phase I Trial of a Replication-Deficient Lymphocytic Choriomeningitis Virus Vector-Based Vaccine Against Human Cytomegalovirus.J Infect Dis2022https://conductscience.org/library/papers/32313928PubMed
1512019106Emergence of resistant human immunodeficiency virus type 1 in patients receiving fusion inhibitor (T-20) monotherapy.Antimicrob Agents Chemother2002https://conductscience.org/library/papers/12019106PubMed
1635783486Safety and immunogenicity of an HIV-1 prefusion-stabilized envelope trimer (Trimer 4571) vaccine in healthy adults: A first-in-human open-label, randomized, dose-escalation, phase 1 clinical trial.EClinicalMedicine2022https://conductscience.org/library/papers/35783486PubMed
1737777519Assessing immunogenicity barriers of the HIV-1 envelope trimer.NPJ Vaccines2023https://conductscience.org/library/papers/37777519PubMed
1834465781A modular self-adjuvanting cancer vaccine combined with an oncolytic vaccine induces potent antitumor immunity.Nat Commun2021https://conductscience.org/library/papers/34465781PubMed
1911861826Enhancing the proteolytic maturation of human immunodeficiency virus type 1 envelope glycoproteins.J Virol2002https://conductscience.org/library/papers/11861826PubMed
2024812275Re-engineering vesicular stomatitis virus to abrogate neurotoxicity, circumvent humoral immunity, and enhance oncolytic potency.Cancer Res2014https://conductscience.org/library/papers/24812275PubMed

See all 50 referencesDownload CSV of references

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Trials
  • Comments and corrections
  • Cited by
  • Genes
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/41398167

GET https://conductscience.org/api/papers/v1/41398167/references?page=2